EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 191 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,768 | -18.9% | 556 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $10,809 | -31.5% | 556 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $15,774 | -29.2% | 556 | -27.0% | 0.00% | 0.0% |
| Q4 2022 | $22,273 | +10.6% | 762 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $20,132 | -40.5% | 762 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $33,856 | -10.2% | 762 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $37,711 | -79.1% | 762 | -78.5% | 0.00% | -50.0% |
| Q4 2021 | $180,206 | -8.7% | 3,539 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $197,405 | +30.3% | 3,539 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $151,469 | +2.5% | 3,539 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $147,718 | -10.4% | 3,539 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $164,811 | +9.6% | 3,539 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $150,337 | -11.5% | 3,539 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $169,801 | +5.1% | 3,539 | +0.7% | 0.00% | 0.0% |
| Q1 2020 | $161,598 | -23.4% | 3,513 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $211,061 | +6.2% | 3,513 | 0.0% | 0.00% | +33.3% |
| Q3 2019 | $198,730 | +1.6% | 3,513 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $195,604 | +10.3% | 3,513 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $177,371 | +25.3% | 3,513 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $141,539 | -41.9% | 3,513 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $243,556 | -99.9% | 3,513 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $265,794,000 | +75.7% | 3,513 | +22.4% | 0.00% | +100.0% |
| Q1 2018 | $151,273,000 | +108729.5% | 2,871 | +10.2% | 0.00% | 0.0% |
| Q4 2017 | $139,000 | -58.6% | 2,606 | -53.7% | 0.00% | 0.0% |
| Q3 2017 | $336,000 | -27.6% | 5,630 | -4.3% | 0.00% | -33.3% |
| Q2 2017 | $464,000 | -10.3% | 5,882 | -5.7% | 0.00% | -25.0% |
| Q1 2017 | $517,000 | +4.4% | 6,236 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $495,000 | +13.3% | 6,236 | 0.0% | 0.00% | +33.3% |
| Q3 2016 | $437,000 | +80.6% | 6,236 | 0.0% | 0.00% | +50.0% |
| Q2 2016 | $242,000 | -4.3% | 6,236 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $253,000 | -54.2% | 6,236 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $553,000 | +19.7% | 6,236 | 0.0% | 0.00% | +33.3% |
| Q3 2015 | $462,000 | -8.7% | 6,236 | -0.3% | 0.00% | -25.0% |
| Q2 2015 | $506,000 | – | 6,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |